Prostaglandin E2 and cysteinyl leukotriene concentrations in sputum: association with asthma severity and eosinophilic inflammation

被引:70
作者
Aggarwal, S. [1 ]
Moodley, Y. P. [1 ]
Thompson, P. J. [1 ]
Misso, N. L. [1 ]
机构
[1] Univ Western Australia, Lung Inst Western Australia, Ctr Asthma Allergy & Resp Res, Perth, WA 6009, Australia
关键词
asthma severity; cysteinyl leukotrienes; eosinophilic airway inflammation; induced sputum; leukotriene E-4; prostaglandin E-2; urine; MAST-CELL ACTIVATION; AIRWAY INFLAMMATION; BRONCHIAL-ASTHMA; ALLERGEN; PGE(2); URINE; MECHANISMS; METABOLITE; EXPRESSION; MODERATE;
D O I
10.1111/j.1365-2222.2009.03386.x
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
P>Background Inflammation of the airways in asthma is associated with the production of cysteinyl leukotrienes (cysLT), prostaglandin (PG)E-2, 8-isoprostane, nitric oxide and other mediators. However, the relationship between asthma severity or eosinophilic inflammation and the concentrations of mediators in sputum is unclear. Objective To assess sputum PGE(2), cysLT, 8-isoprostane and nitrate concentrations, as well as urinary leukotriene (LT)E-4 and 9 alpha,11 beta-prostaglandin (PG)F-2 concentrations, in patients with differing severities of asthma and eosinophilic or non-eosinophilic airway inflammation. Methods Inflammatory cells in sputum were assessed in 12 patients with mild, 14 with moderate and 12 with severe persistent asthma, as well as in 13 control subjects. Asthmatic patients were categorized into those with eosinophilic or non-eosinophilic airway inflammation. Sputum PGE(2), cysLT and 8-isoprostane, and urinary LTE4 were extracted on immunoaffinity sorbents, and the concentrations of all mediators were measured using enzyme immunoassays. Sputum nitrate concentrations were measured on a chemiluminescence analyzer. Results Sputum PGE(2) concentrations were higher in both moderate (1710 pg/mL) and severe asthmatic (1590 pg/mL) compared with control subjects (827 pg/mL) (P < 0.05). CysLT concentrations were higher in moderate asthmatic compared with control or severe asthmatic subjects (P < 0.05). Sputum PGE(2) concentrations were lower in patients with eosinophilic (1180 pg/mL) compared with non-eosinophilic airway inflammation (2520 pg/mL) (P=0.02). In contrast, sputum cysLT and urinary LTE4 concentrations were higher in those with eosinophilic airway inflammation (P < 0.05). Forced expiratory volume in 1 s was inversely correlated with sputum eosinophils in all asthmatic patients (r(s)=-0.5, P=0.002). There were no significant differences in sputum 8-isoprostane or nitrate concentrations. Conclusions Increased airway concentrations of PGE(2) are consistent with the hypothesis that PGE(2) has a bronchoprotective and anti-inflammatory role in patients with more severe asthma. A reduced PGE(2) to cysLT ratio in the airways may adversely affect lung function and contribute to persistence of symptoms and airway remodelling in patients with eosinophilic airway inflammation. Cite this as: S. Aggarwal, Y. P. Moodley, P. J. Thompson and N. L. Misso, Clinical & Experimental Allergy, 2010 (40) 85-93.
引用
收藏
页码:85 / 93
页数:9
相关论文
共 39 条
[1]   Low sputum eosinophils predict the lack of response to beclomethasone in symptomatic asthmatic patients [J].
Bacci, E ;
Cianchetti, S ;
Bartoli, M ;
Dente, FL ;
Di Franco, A ;
Vagagaini, B ;
Paggiaro, P .
CHEST, 2006, 129 (03) :565-572
[2]   Clinical assessment of asthma severity partially corresponds to sputum eosirophilic airway inflammation [J].
Bartoli, ML ;
Bacci, E ;
Carnevali, S ;
Cianchetti, S ;
Dente, FL ;
Di Franco, A ;
Giannini, D ;
Taccola, M ;
Vagaggini, B ;
Paggiaro, PL .
RESPIRATORY MEDICINE, 2004, 98 (02) :184-193
[3]   Plasma 9α, 11β-PGF2, a PGD2 metabolite, as a sensitive marker of mast cell activation by allergen in bronchial asthma [J].
Bochenek, G ;
Nizankowska, E ;
Gielicz, A ;
Swierczynska, M ;
Szczeklik, A .
THORAX, 2004, 59 (06) :459-464
[4]   A controlled study of 9α,11β-PGF2 (a prostaglandin D2 metabolite) in plasma and urine of patients with bronchial asthma and healthy controls after aspirin challenge [J].
Bochenek, G ;
Nagraba, K ;
Nizankowska, E ;
Szczeklik, A .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2003, 111 (04) :743-749
[5]   INDIRECT EVIDENCE OF BRONCHIAL INFLAMMATION ASSESSED BY TITRATION OF INFLAMMATORY MEDIATORS IN BAL FLUID OF PATIENTS WITH ASTHMA [J].
BOUSQUET, J ;
CHANEZ, P ;
LACOSTE, JY ;
ENANDER, I ;
VENGE, P ;
PETERSON, C ;
AHLSTEDT, S ;
MICHEL, FB ;
GODARD, P .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1991, 88 (04) :649-660
[6]   Asthma - From bronchoconstriction to airways inflammation and remodeling [J].
Bousquet, J ;
Jeffery, PK ;
Busse, WW ;
Johnson, M ;
Vignola, AM .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2000, 161 (05) :1720-1745
[7]   Induced sputum inflammatory mediator concentrations in eosinophilic bronchitis and asthma [J].
Brichtling, CE ;
Ward, R ;
Woltmann, G ;
Bradding, P ;
Sheller, JR ;
Dworski, R ;
Pavord, ID .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2000, 162 (03) :878-882
[8]   Monitoring mast cell activation by prostaglandin D2 in vivo [J].
Dahlèn, SE ;
Kumlin, M .
THORAX, 2004, 59 (06) :453-455
[9]  
Dahlén SE, 1998, CLIN EXP ALLERGY, V28, P129
[10]   Non-eosinophilic asthma: importance and possible mechanisms [J].
Douwes, J ;
Gibson, P ;
Pekkanen, J ;
Pearce, N .
THORAX, 2002, 57 (07) :643-648